Moderna's booster plan comes into focus with pre-print studies in immunocompromised populations, Delta breakthroughs
Moderna submitted initial data to the FDA for its Covid-19 vaccine booster plan earlier this week, and that plan is sharpening into view following several published pre-prints over the last few weeks.
Studies outlining the Moderna vaccine’s effectiveness in different immunocompromised populations, as well as examining the shots’ ability to prevent breakthrough infections, have come to light recently. And most, if not all, of the pre-prints show Moderna’s shot netting higher rates at preventing Covid-19 than the jab from Pfizer and BioNTech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
